Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay

Nature volume 465, pages 227–230 (2010)Cite this article

Subjects

Abstract

The main reason why tumours are not controlled by the immune system is that, unlike pathogens, they do not express potent tumour rejection antigens (TRAs). Tumour vaccination aims at stimulating a systemic immune response targeted to, mostly weak, antigens expressed in the disseminated tumour lesions. Main challenges in developing effective vaccination protocols are the identification of potent and broadly expressed TRAs1,2,3 and effective adjuvants to stimulate a robust and durable immune response4,5,6. Here we describe an alternative approach in which the expression of new, and thereby potent, antigens are induced in tumour cells by inhibiting nonsense-mediated messenger RNA decay (NMD)7,8,9,10. Small interfering RNA (siRNA)-mediated inhibition of NMD in tumour cells led to the expression of new antigenic determinants and their immune-mediated rejection. In subcutaneous and metastatic tumour models, tumour-targeted delivery of NMD factor-specific siRNAs conjugated to oligonucleotide aptamer ligands led to significant inhibition of tumour growth that was superior to that of vaccination with granulocyte–macrophage colony-stimulating factor (GM-CSF)-expressing irradiated tumour cells11, and could be further enhanced by co-stimulation. Tumour-targeted NMD inhibition forms the basis of a simple, broadly useful, and clinically feasible approach to enhance the antigenicity of disseminated tumours leading to their immune recognition and rejection. The cell-free chemically synthesized oligonucleotide backbone of aptamer–siRNAs reduces the risk of immunogenicity and enhances the feasibility of generating reagents suitable for clinical use.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Expression of Upf2 or Smg1 shRNA in CT26 tumour cells leads to immune-mediated inhibition of tumour growth.
Figure 2: Inhibition of tumour growth in mice treated with PSMA aptamer targeted Upf2 and Smg1 siRNAs.
Figure 3: PSMA aptamer– Smg1 siRNA rejection of PSMA-expressing, but not parental, CT26 tumour cells.
Figure 4: Comparison of PSMA aptamer– Smg1 siRNA treatment to vaccination with GM-CSF expressing irradiated tumour cells.

References

  1. Gilboa, E. The makings of a tumor rejection antigen. Immunity 11, 263–270 (1999)

    Article  CAS  PubMed  Google Scholar 

  2. Novellino, L., Castelli, C. & Parmiani, G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 54, 187–207 (2005)

    Article  CAS  PubMed  Google Scholar 

  3. Schietinger, A., Philip, M. & Schreiber, H. Specificity in cancer immunotherapy. Semin. Immunol. 20, 276–285 (2008)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gilboa, E. The promise of cancer vaccines. Nature Rev. Cancer 4, 401–411 (2004)

    Article  CAS  Google Scholar 

  5. Melief, C. J. Cancer immunotherapy by dendritic cells. Immunity 29, 372–383 (2008)

    Article  CAS  PubMed  Google Scholar 

  6. Pardoll, D. M. Spinning molecular immunology into successful immunotherapy. Nature Rev. Immunol. 2, 227–238 (2002)

    Article  CAS  Google Scholar 

  7. Frischmeyer, P. A. & Dietz, H. C. Nonsense-mediated mRNA decay in health and disease. Hum. Mol. Genet. 8, 1893–1900 (1999)

    Article  CAS  PubMed  Google Scholar 

  8. Behm-Ansmant, I. et al. mRNA quality control: an ancient machinery recognizes and degrades mRNAs with nonsense codons. FEBS Lett. 581, 2845–2853 (2007)

    Article  CAS  PubMed  Google Scholar 

  9. Maquat, L. E. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nature Rev. Mol. Cell Biol. 5, 89–99 (2004)

    Article  CAS  Google Scholar 

  10. Mühlemann, O., Eberle, A. B., Stalder, L. & Zamudio Orozco, R. Recognition and elimination of nonsense mRNA. Biochim. Biophys. Acta 1779, 538–549 (2008)

    Article  PubMed  Google Scholar 

  11. Jinushi, M., Hodi, F. S. & Dranoff, G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol. Rev. 222, 287–298 (2008)

    Article  CAS  PubMed  Google Scholar 

  12. El-Bchiri, J. et al. Nonsense-mediated mRNA decay impacts MSI-driven carcinogenesis and anti-tumor immunity in colorectal cancers. PLoS One 3, e2583 (2008)

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  13. Mendell, J. T., Sharifi, N. A., Meyers, J. L., Martinez-Murillo, F. & Dietz, H. C. Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nature Genet. 36, 1073–1078 (2004)

    Article  CAS  PubMed  Google Scholar 

  14. Usuki, F. et al. Specific inhibition of nonsense-mediated mRNA decay components, SMG-1 or Upf1, rescues the phenotype of Ullrich disease fibroblasts. Mol. Ther. 14, 351–360 (2006)

    Article  CAS  PubMed  Google Scholar 

  15. Wittmann, J., Hol, E. M. & Jack, H. M. hUPF2 silencing identifies physiologic substrates of mammalian nonsense-mediated mRNA decay. Mol. Cell. Biol. 26, 1272–1287 (2006)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Isken, O. & Maquat, L. E. The multiple lives of NMD factors: balancing roles in gene and genome regulation. Nature Rev. Genet. 9, 699–712 (2008)

    Article  CAS  PubMed  Google Scholar 

  17. Duval, A. & Hamelin, R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res. 62, 2447–2454 (2002)

    CAS  PubMed  Google Scholar 

  18. Aagaard, L. et al. A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha. Mol. Ther. 15, 938–945 (2007)

    Article  CAS  PubMed  Google Scholar 

  19. Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569–580 (2003)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hogquist, K. A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17–27 (1994)

    Article  CAS  PubMed  Google Scholar 

  21. Gold, L. Oligonucleotides as research, diagnostic, and therapeutic agents. J. Biol. Chem. 270, 13581–13584 (1995)

    Article  CAS  PubMed  Google Scholar 

  22. Nimjee, S. M., Rusconi, C. P. & Sullenger, B. A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56, 555–583 (2005)

    Article  CAS  PubMed  Google Scholar 

  23. Lupold, S. E., Hicke, B. J., Lin, Y. & Coffey, D. S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62, 4029–4033 (2002)

    CAS  PubMed  Google Scholar 

  24. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783–801 (2006)

    Article  CAS  PubMed  Google Scholar 

  25. Judge, A. D. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature Biotechnol. 23, 457–462 (2005)

    Article  CAS  Google Scholar 

  26. McNamara, J. O. et al. Multivalent 4-1BB binding aptamers costimulate CD8 T cells and inhibit tumor growth in mice. J. Clin. Invest. 118, 376–386 (2008)

    Article  CAS  PubMed  Google Scholar 

  27. Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539–3543 (1993)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  28. van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355–366 (1999)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Quezada, S. A., Peggs, K. S., Curran, M. A. & Allison, J. P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116, 1935–1945 (2006)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Aagaard, L. et al. A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha. Mol. Ther. 15, 938–945 (2007)

    Article  CAS  PubMed  Google Scholar 

  31. Li, M. J. & Rossi, J. J. Lentiviral vector delivery of recombinant small interfering RNA expression cassettes. Methods Enzymol. 392, 218–226 (2005)

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank J. Zhang for assistance in the mouse studies, A.-M. Jegg for technical assistance in characterizing Smg1 siRNAs, J. Rossi for advising in the design of aptamer–siRNA conjugates, and S. Nair and D. Boczkowski for advice in performing T-cell assays. This work was supported by the Dodson foundation and the Sylvester Comprehensive Cancer Center (Medical School, University of Miami).

Author information

Authors and Affiliations

  1. Department of Microbiology & Immunology, Dodson Interdisciplinary Immunotherapy Institute, University of Miami Miller School of Medicine Miami, Florida 33134, USA

    Fernando Pastor, Despina Kolonias & Eli Gilboa

  2. Department of Internal Medicine and Department of Radiation Oncology, Molecular and Cellular Biology Program, University of Iowa, Iowa City, Iowa 52242, USA,

    Paloma H. Giangrande

Authors
  1. Fernando Pastor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Despina Kolonias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paloma H. Giangrande
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eli Gilboa
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

F.P. suggested the approach and was responsible for designing the aptamer–siRNA conjugates and interpreting the results, D.K. was responsible for the mouse studies, P.H.G. helped design the aptamer–siRNA conjugates, and E.G. oversaw experimental design, data analysis, and wrote the manuscript.

Corresponding author

Correspondence to Eli Gilboa.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information

This file contains Supplementary Figures 1-8 with legends, a Supplementary Discussion and References. (PDF 1527 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pastor, F., Kolonias, D., Giangrande, P. et al. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 465, 227–230 (2010). https://doi.org/10.1038/nature08999

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature08999

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer